Filippo Pietrantonio
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Filippo Pietrantonio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:49 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07763171 · Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-Ovest · not yet recruiting · Gastroesophageal Adenocarcinoma · principal investigator
- Ph2NCT07407465 · Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.Gruppo Oncologico del Nord-Ovest · recruiting · Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma · principal investigator
- Ph2NCT06253650 · Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual DiseaseGruppo Oncologico del Nord-Ovest · recruiting · Gastric Cancer, HER2-positive Gastric Cancer · principal investigator
- Ph2NCT05845450 · Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Gruppo Oncologico del Nord-Ovest · recruiting · Colorectal Cancer, Resectable Colorectal Carcinoma · principal investigator
- Ph2NCT05031975 · Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant ChemotherapyFondazione IRCCS Istituto Nazionale dei Tumori, Milano · unknown · Colorectal Cancer · principal investigator
- Ph2NCT04817826 · TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.Gruppo Oncologico del Nord-Ovest · active not recruiting · Gastric Cancer, Microsatellite Instability · principal investigator
- Ph1/Ph2NCT04689347 · 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · recruiting · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT03832621 · NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerFondazione IRCCS Istituto Nazionale dei Tumori, Milano · completed · Metastatic Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:49 UTC. The ranking covers the 200 most relevant of 90 PubMed records, and a shared surname and initials can bring in a namesake. All 90 on PubMed
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.N Engl J Med · 2023359 citationsRCR 28.6
- 351 citationsRCR 12.1
- 288 citationsRCR 12.6
- 246 citationsRCR 14.8
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Nat Med · 2022236 citationsRCR 14.7
- Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.JAMA Oncol · 2021147 citationsRCR 7.5
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.Lancet Oncol · 2024144 citationsRCR 16.4
- Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.Cancer Discov · 2022121 citationsRCR 6.7
- 120 citationsRCR 7.1
- Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.J Clin Oncol · 2019108 citationsRCR 3.3